Long-term Clinical & Biological Evaluation of Patients With Severe Forms

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05534776` - Validation of 5-Point Investigator Global Assessments for Pemphigus
Terminated	`NCT00278642` - Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders	Phase 1
Not yet recruiting	`NCT05898308` - Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus	Phase 4
Terminated	`NCT01559155` - Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid
Active, not recruiting	`NCT01974518` - Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus	Phase 3
Recruiting	`NCT05284929` - Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
Recruiting	`NCT05954416` - FARD (RaDiCo Cohort) (RaDiCo-FARD)
Completed	`NCT00283712` - Use of Infliximab for the Treatment of Pemphigus Vulgaris	Phase 2
Not yet recruiting	`NCT06285435` - Coagulation Activation in Patients With Pemphigus
Completed	`NCT00960713` - The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders	N/A
Completed	`NCT00213512` - Effect of Anti CD20 in Pemphigus Desease	Phase 2/Phase 3
Active, not recruiting	`NCT04400994` - IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus	Phase 2
Recruiting	`NCT02237313` - Identification of Vulnerability Factors in the Course of Pemphigus Patients	N/A
Terminated	`NCT03075904` - A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)	Phase 1/Phase 2
Terminated	`NCT03762265` - A Study of PRN1008 in Patients With Pemphigus	Phase 3
Recruiting	`NCT02365675` - Wound Dressings for Pemphigus and Pemphigoid	N/A
Recruiting	`NCT01338103` - Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex	N/A
Active, not recruiting	`NCT00656656` - Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus	Phase 2
Completed	`NCT00127764` - European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus	Phase 2/Phase 3
Recruiting	`NCT01313923` - Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus	Phase 0

NCT number	NCT01299857
Study type	Interventional
Source	University Hospital, Rouen
Contact
Status	Completed
Phase	Phase 3
Start date	June 2011
Completion date	June 2012

Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab — Suiviritux

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms